Facebook Twitter RSS Feed

You are here

Structural Heart

 - heart

Transcatheter mitral valve implantation looks like the next frontier in treatments for patients who are at high risk for surgical valve repair or replacement. In a first-in-man report, physicians demonstrated that a transapical approach is technically feasible and potentially safe.

 - Chart trending down

Initiating a radiation safety protocol in their congenital heart center reduced the cumulative radiation dose in patients undergoing catheterizations by 61 percent, cardiologists reported in the November issue of Catheterization and Cardiovascular Interventions.

 - hospitalist and patient

Almost one in five patients who undergo cardiac surgery get readmitted, with the vast majority rehospitalized within 30 days. The findings, published in the October issue of the Annals of Thoracic Surgery, have implications for future quality measures.

 - Patient

Mechanical and bioprosthetic aortic valve replacements were found to be equally safe and effective for patients aged 50 to 59 years, according to a study published Oct. 1 in JAMA. No difference was seen in stroke or long-term survival rates between the two replacement options.

 - Lotus

A repositionable and retrievable valve proved safe and effective at 30 days in high-risk patients who underwent transcatheter aortic valve replacement. Results from the REPRISE II study were published in the Sept. 30 issue of the Journal of the American College of Cardiology.


More Stories

Women bore brunt of initial NCD for TAVR

Limiting access to transcatheter aortic valve replacement (TAVR) therapy to inoperable patients suitable for only a transfemoral approach reduced the number of patients who received care, particularly women, in a study that evaluated the effect of the national coverage determination (NCD). 

Surgeons warn against use of Mitroflow valve in young patients

Children’s hospital physicians cautioned surgeons against implanting the Mitroflow bioprosthetic aortic valve in young patients who undergo aortic valve replacement and recommended vigilant surveillance of those who already have the device.

Congenital heart disease longevity increasing in Quebec

People with congenital heart disease are living longer and both birth and longevity rates in Quebec and the rest of Canada are comparable to statistics from other industrialized nations. Over time, this is leading to growth of an aging congenital heart disease population, particularly for those with severe disease with comorbid conditions, according to a study published online June 18 in Circulation.

Antidepressants not likely to increase risk of cardiac birth defects

The risk of children developing heart defects due to maternal antidepressant use in the first trimester may be lower than originally thought, according to a study published June 18 in the New England Journal of Medicine. These findings challenge the FDA’s decision to classify selective serotonin-reuptake inhibitors as Category D medications (evidence of human fetal risk, but benefits may warrant use) in pregnancy.

FDA approves next-gen Sapien valve

The FDA has given the green light to Edwards Lifesciences to market its next-generation transcatheter aortic valve replacement (TAVR) device, the Sapien XT, for treatment in inoperable and high-risk patients with severe aortic stenosis.

2D echo may lead to inaccurate sizing in half of TAVR patients

Almost half the patients implanted with a transcatheter aortic valve replacement (TAVR) device received the wrong valve size in a study that compared oversizing using transesophageal echocardiography (TEE) with multislice CT. As a result, the patients received a transcatheter heart valve that was too small.

FDA OKs CoreValve for high-risk patients

The FDA approved the CoreValve device for transcatheter aortic valve replacement (TAVR) in high-risk patients with severe aortic stenosis without a review from an expert panel. While the favorable decision was expected, the road to it developed a few potholes.

Tool IDs patients with poor outcomes after TAVR

A model that includes quality of life (QoL) in its assessment predicted with moderate discrimination patients who likely would have poor outcomes after undergoing transcatheter aortic valve replacement (TAVR), according to results published online May 23 in Circulation.

TAVR triumphs

This week, two titans in transcatheter aortic valve replacement (TAVR) settled a feud over patents. One beneficiary of that agreement may be TAVR itself.

TAVR détente: Edwards, Medtronic settle patent dispute

Edwards Lifesciences and Medtronic reached a cross-license settlement over transcatheter aortic valve replacement (TAVR) devices with provisions that should put their patent dispute to rest.

CMS supports coverage for transcatheter mitral devices

The Centers for Medicare & Medicaid Services (CMS) is proposing to cover transcatheter mitral valve repair, but only if certain conditions are met.

AATS: No signs of risk creep with TAVR

Fears that physicians may be treating patients who are suitable candidates for standard care with less invasive transcatheter aortic valve replacement (TAVR) may be allayed, based on results presented April 28 at the American Association of Thoracic Surgery meeting in Toronto.

AATS: Complex cardiac surgeries may require continued training

Cardiac surgeons may benefit from continuous training if they perform complex or rare procedures, according to an abstract presented April 28 at the American Association for Thoracic Surgery meeting in Toronto.

FDA approves valve treated to prevent calcification

The FDA approved a bioprosthetic heart valve that is treated to improve durability.

Court grants delay on CoreValve injunction

Does CoreValve have a pulse? A federal court of appeals granted Medtronic’s request to delay implementation of a preliminary injunction that would limit the sale of the device in the U.S.

Judge limits sale of CoreValve but grants delay

A federal court called for a preliminary injunction limiting the sale of the CoreValve device in the U.S. but granted a reprieve before the injunction is scheduled to go into effect.

Technically inoperable patients fare best after TAVR

Transcatheter aortic valve replacement (TAVR) patients who are inoperable because of technical reasons have better outcomes than TAVR patients who are clinically inoperable, a finding that could help identify patients likely to reap the greatest benefit from the procedure.

European office revokes patent on TAVR valve

In the latest in a battle between the titans in transcatheter aortic valve replacement (TAVR), the European Patent Office invalidated a patent at the heart of Edwards Lifesciences’ infringement case against Medtronic.

Valvular heart disease guidelines add TAVR, updates

Recently released practice guidelines for treating patients with valvular heart disease forged new ground on several fronts. For the first time, they included recommendations for transcatheter aortic valve replacement (TAVR) as well as a new classification system.

Aortic stenosis: Lifelong learning in the 21st century

Transcatheter aortic valve replacement (TAVR) for eligible patients with severe aortic stenosis holds great promise but much still needs to be learned. The American College of Cardiology (ACC) is piloting an initiative that is designed to help valve centers in the U.S. improve quality and achieve good outcomes.